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1. Introduction 
Since the dawn of time Homo sapiens have collected human body-parts for a variety of 
reasons (Lassila &Branch, 2006; Aquaron et al., 2009; Daily Telegraph, 2011). Similarly, 
representations of pathological lesions have been collected for educational purposes for at 
least three hundred years (e.g. the Hunterian Museum in Glasgow has preserved plaster 
casts of diseased tissues). A biobank is a generic term to describe any collection of biological 
materials and may take many forms, ranging from the preservation of plant seeds (e.g the 
Svalbard Global Seed Vault, Norway) or, the storage of human materials for transplants (e.g. 
corneal biobanks). Others collect human materials for artificial insemination (sperm, eggs 
and embryos), for forensic investigations and animal materials to assist in the preservation 
of endangered species such as the Iberian lynx (Leon-Quinto et al., 2009). Some biobanks 
only collect a single type of sample such as DNA (genebanks), whilst others archive a wide 
variety of clinical materials. Until recently the modus operandi of most medical researchers 
was to use fresh clinical materials to test a specific hypothesis. The premise was either 
proven, or not, and then the process repeated to answer subsequent questions. This 
approach is incredibly wasteful since materials not directly needed to test each argument 
were discarded. In contrast, clinical biobanks can archive and distribute complete sets of 
materials from patients with diseases to multiple researchers thereby maximising the benefit 
of every donation. They can also revolutionise the understanding of very rare conditions by 
gradually accumulating sufficient numbers of samples –or, by the exchange of samples 
between multiple biobanks (networking) - to permit statistically-significant conclusions to 
be derived.  
These advantages of biobanks were recognized by Time magazine as ‘one of the ten ideas 
that are changing the world right now’ (Park, 2009). This Chapter will be confined to those 
issues confronting biobanks which collect human materials for medical research. Such 
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archives can be subdivided into those which have the aim of answering one specific 
research question (e.g. the Multiple Sclerosis Brain bank) as opposed to systematic 
biobanks such as the Infectious Diseases Biobank (IDB) at King’s College London (KCL) 
(Williams et al., 2009), which collects clinical materials with no specific research question 
in mind. The growing popularity of biobanks in medical research in recent years has 
inevitably raised new and important ethic and legal questions regarding how they should 
be managed and regulated. For example, recently, the German Ethics Council has 
proposed that biobanks should be regulated on the basis of five ‘pillars’ including the 
concepts of: confidentiality; open informed consent; careful ethics review; sample quality-
assurance; and, a transparency of the biobank’s goals (Deutscher Ethikrat, 2010).  Here 
some of the most contentious ethico-legal issues facing clinical archives are considered, 
including: (i) the nature of the contract (i.e. informed consent) between the subject and the 
researcher; (ii) the concept of property or ownership rights in respect to body tissues and 
fluids; (iii) the duty of care of a biobank to the donor, the sample, the researcher and, 
society. This is contextualised against historic turning points which have led to the 
regulatory structures currently in force in the UK. Finally, the organization of the UK’s 
IDB at KCL is described and proposed as a model system for facilitating research into 
infectious diseases. 
2. Ethical considerations in human biobanking 
2.1 Novel challenges associated with biobanking 
The idea of a biobank to facilitate medical research would appear to be a worthwhile and 
commendable activity to most people. However, the establishment of such archives raise not 
only many of the same ethical problems that face the medical community (particularly those 
involved in recruiting organ donations), but also some unique questions of their own, for 
example:  
- How can a volunteer provide fully ‘informed consent’ when neither they nor the 
recruiter have any idea about the nature of future research which will be performed on 
the donated sample?  
- Donating a sample for no pressing medical reason could be questioned since this 
relatively benign procedure carries an appreciable risk of adverse events (in one study 
the rate was 0.59% of 89,000 blood donations: of these ~15% were haematomas and 77% 
vaso-vagal reflex: Garozzo et al., 2010).   
- Who actually owns the donated sample?  
- Does a donated sample have a commercial value and can it be sold?  
- What happens if research discovers that a volunteer has a potentially deadly disease?  
- How can biobanks insure that they are representative of the local community?  
- Should biobank samples be used for ‘trivial’ (e.g. cosmetics development) or 
’controversial’ (e.g. stem cell, cloning etc.) research?  
2.2 An ethical framework 
To answer such questions biobanks (and their regulators) must draw on contemporary 
ethical codes, attitudes and opinions to provide guidance to best practice. Whilst this 
approach can provide discussion points to it does not always produce definitive answers 
(Gillon, 1985). The earliest consideration of medical ethics was probably the Hippocratic 
Oath, which introduced the concepts of respecting patients as individuals and doing no 
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harm (Farnell, 2004). Similar sentiments are expressed in the payer of Maimonides, 
originally believed to have been written by the 12th-century physician-philosopher 
(Friedenwald, 1917). More probably, this prayer was written by M. Herz, a physician and 
pupil of the Konigsberg philosopher Immanuel Kant, as print versions can only be traced 
back until 1793. More contemporary views on medical ethics were crystallized in a 1902 
book by Dr Albert Moll on ‘Ethics of the Physician:’ Hahn, 1984). Two major ethical issues 
raised by biobanks revolve around consent and the ownership in human tissues.  
The justification for consent stems from the notion of personal sovereignty; the exclusive 
right an individual holds over their own person. This concept is historically rooted in liberal 
and political thought, as noted by JS Mills: ‘over himself, over his own body and mind, the 
individual is sovereign’ (Mills 1972). Equally though, Kant believed that the humans ‘exists as 
an end in itself, not merely as a means to be used by this or that will at its discretion’ (Gregor, 1998). 
Indeed, personal sovereignty now serves as the justification for the majority of articles 
enshrined in the Universal Declaration of Human Rights. Whilst consent is a necessary 
component in everyday life and medical research it is debatable how ‘informed’ consent 
need be. On the one extreme consent procured through misleading information (or under 
duress) cannot be considered valid. At the other end of the scale an individual may be 
informed of the risks and side effects of a medical procedure, but is not expected to 
comprehend the full complexities of the issues. Consent is often reduced to a subtle 
paternalism in regards to the unequal position of patient-subject to the researcher, as well as 
addressing how ‘informed’ a research project can be.  
Although respecting personal sovereignty is necessary, there are also ethical principles in 
favour of a communal duty to society. As the aim of a biobank is to facilitate medical 
research (which in turn will aid the development of future treatments for the general good 
of society), the question arises as to whether there is an obligation to assist such endeavours. 
As Mills states ‘there are also many positive acts for the benefit of others that he may rightfully be 
compelled to perform:  such as to give evidence in courts of justice; to bear his fair share in a common 
defence; or in any other joint work necessary to the interests of the society of which he enjoys the 
protection’ (Mills, 1972). Thus, respecting personal sovereignty does not negate the argument 
in favour of a public duty to assist such endeavours. Indeed, utilitarian arguments for the 
‘greatest good for the greatest number’ (Bentham’s ‘felicific calculus’: Mitchell, 1918) and 
Kant’s transcendental deduction of a moral duty (Paton, 1948) may to some degree also 
imply an obligation to donate samples to a biobank.  
Locke’s concept of property is based on the premise that an individual owns the labour of 
their body, which when mixed with something in nature, confers a property right in the 
produced object. Indeed a Lockean justification of property rights was accepted in the US 
case John Moore v The Regents of the University of California (1990) as a foundation for a claim 
on a human cell-line. Thus, Lockean justification for ownership of samples in a biobank 
could be constructed in a similar fashion; the labour expended in collecting, preparing and 
storing A biobank’s samples confers a right of ownership. Although a degree of ownership 
exists in relation to human samples it is better to conceive this as conditional ownership (or 
‘custodianship’) rather than an absolute ownership. 
2.3 Some historical precedents leading to research ethics regulation 
Self-regulation of biobanks based upon general ethical principles may seem a reasonable 
approach to managing a few samples of blood or urine which have been willingly donated 
for research. However, a series of notorious cases from the 19th century up to the present 
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day have so shocked the public that legislation of medical ethics and the storage of human 
body parts became inevitable: some of the most infamous cases are outlined below. 
Body-snatching: The UK Murder Act of 1752 meant that the only legal source of corpses for 
anatomy was those of executed prisoners: however, this was insufficient to supply the 
demand from medical schools. Stealing a corpse was only regarded as a minor crime and 
thus evolved into a lucrative business. In 1827/8, the Edinburgh grave-robbers Burke and 
Hare realized that institutions paid more for fresh corpses and thus graduated from body-
snatching to murder in order to meet this demand (Lancet, 1829; Howard & Smith, 2004). 
The subsequent conviction of Burke in 1829 led to the UK Anatomy Act of 1832 which 
stipulated that anyone practising anatomy must hold a licence and be responsible for the 
correct treatment of corpses. This act was repealed by the Anatomy act of 1984 which, in 
turn, was replaced by the Human Tissue Act of 2004 (below). 
Genocide: In the 1930s/40s the National Socialist German Worker’s party (NSDAP) became 
obsessed with the ideas of social Darwinism, eugenics and the Nietzsche concept of 
‘superman’ (Taha, 2005). On this basis the regime initially justified killing those with 
congenital defects in the T4 (Tiergarten-4) euthenasia programme (Freidlander, 1995). This 
was criminal programme was subsequently extended to include anyone that the NSDAP 
deemed ‘sub-human’ (political opponents, Russian prisoners of war, and, notably the near 
genocides of European Jews and Roma: Bachrach, 2004). As part of this holocaust some 
victims were also subjected to non-consensual medical experiments (e.g. LD50 type testing 
of humans exposed to hypobaric or hypothermic conditions). Additionally, the NSDAP 
also assembled a collection of skeletons from euthanized prisoners for the Institute of 
Racial Hygiene to act as a historic record (and the basis for scientific study of) extinct 
human ‘races’. At the end of the war the Nuremberg ‘Doctors Trial’ sentenced some of 
those responsible and resulted in the development of the Nuremberg code of practice for 
research involving humans (Table 1: US Government Printing Office, 1949). This is an 
important document since it has served as the basis of almost all subsequent refinements 
in medical ethics such as the most recent version of the Declaration of Helsinki (World 
Medical Association [WMA], 2009).  
Unit 731: A less-well publicised series of medical crimes of the Second World War 
included those perpetrated by the Imperial Japanese Army’s Unit 731. This was 
euphemistically named the ‘Epidemic Prevention and Water Purification Department’ 
of the Kwantung Army Group in Harbin, occupied China (Alibewk & Handelman, 
1999). This unit experimented on over 10,000 humans in studies involving conscious, 
non-anaesthetised, vivisections, weapons testing (e.g. the effects of flamethrowers, hand 
grenades etc. upon live humans), as well as bio-weapons research (Harris, 1994; Kristof, 
1995; Barrenblat, 2004). 
Tuskagee syphilis study: A study of 400 poor African-American men with syphilis was 
initiated in 1932. To induce participation, recruits were given free medical care, meals and 
burials and in return provided samples of blood and cerebro-spinal fluids to researchers 
(Roy, 1995; Crenner, 2011). At no point were the recruits informed that they had syphilis, 
nor were they treated for it. The 40-year study was particularly controversial because the 
researchers failed to treat patients even after the discovery that penicillin was an effective 
cure. In 2010 it was subsequently revealed that in Guatemala the same study had been 
extended, between 1946-1948, to include actually infecting prisoners, soldiers, and 
patients in a mental hospital. A total of 696 men and women were exposed to syphilis 
without their informed consent. As a direct result of these revelations the US Congress 
passed the National Research Act in 1974 and created a commission to study construct 
regulations governing studies which involve human participants (Prograis, 2010). 
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1. The voluntary consent of the human subject is absolutely essential. This means that 
the person involved should have legal capacity to give consent; should be able to exercise 
free power of choice, without the intervention of any element of force, fraud, deceit, 
duress, over-reaching, or other ulterior form of coercion; and should have sufficient 
knowledge and comprehension of the elements of the subject matter involved as to 
enable him/her to make an understanding and enlightened decision. This latter element 
requires that before the acceptance of an affirmative decision by the experimental subject 
there should be made known to him the nature, duration, and purpose of the experiment; 
the method and means by which it is to be conducted; all inconveniences and hazards 
reasonable expected; and the effects upon his health which may possibly arise from 
participation. The duty and responsibility for ascertaining the quality of the consent rests 
upon each individual who initiates, directs or engages in the experiment. It is a personal 
duty and responsibility which may not be delegated to another with impunity. 
2. The experiment should be such as to yield fruitful results for the good of society, 
unprocurable by other methods or means of study, and not random and unnecessary in 
nature. 
3. The experiment should be so designed and based on the results of animal 
experimentation and a knowledge of the natural history of the disease or other problem 
under study that the anticipated results will justify the performance of the experiment. 
4. The experiment should be so conducted as to avoid all unnecessary physical and 
mental suffering and injury.
5. No experiment should be conducted where there is a prior reason to believe that 
death or disabling injury will occur; except, perhaps, in those experiments where the 
experimental physicians also serve as subjects. 
6. The degree of risk to be taken should never exceed that determined by the 
humanitarian importance of the problem to be solved by the experiment.
7. Proper preparations should be made and adequate facilities provided to protect the 
experimental subject against even remote possibilities of injury, disability, or death. 
8. The experiment should be conducted only by scientifically qualified persons. The 
highest degree of skill and care should be required through all stages of the experiment of 
those who conduct or engage in the experiment. 
9. During the course of the experiment the human subject should be at liberty to bring 
the experiment to an end if he has reached the physical or mental state where 
continuation of the experiment seems to him to be impossible. 
10. During the course of the experiment the scientist in charge must be prepared to 
terminate the experiment at any stage, if he has probable cause to believe, in the exercise of 
the good faith, superior skill and careful judgment required of him that a continuation of 
the experiment is likely to result in injury, disability, or death to the experimental subject. 
 
Table 1. The Nuremberg code for medical research involving humans. 
Alder Hey hospital scandal: An investigation into the retention of hearts at hospitals in 
Bristol UK in the early 1990s led to a public inquiry. This subsequently found that a 
large number of hearts were also being held by the Alder Hey Children's Hospital and 
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the Walton Hospital. In 2001 the Redfern Report (Royal Liverpool Hospital Children’s 
enquiry, 2001) was published and this led to public outcry when it was revealed that 
Prof van Velzen had archived organs from every child subjected to a post mortem. 
Around 500,000 tissue samples were being held without any realistic likelihood of them 
ever being used for research. These revelations led to the creation of the Human Tissue 
Authority and the 2004 Human Tissue Act and in the UK.  
Desecration of Alaister Cooke’s remains: In 2005 it was discovered that the bones of Alaister 
Cooke (a distinguished BBC correspondent) and those of others had been surgically 
excised without permission prior to cremation by Biomedical Tissue Services Ltd. (Smit, 
2008). The company then sold the treated bones for use as surgical grafts. Cooke was 
suffering from bone cancer when he died which would have made his tissues unsuitable 
for such a purpose. Reports revealed that the people involved in selling the bones altered 
his death certificate to hide this fact: subsequently M. Mastromarino, a former New Jersey 
dentist, was sentenced to between 18 and 54 years imprisonment. 
The more contemporary of these cases illustrate that body-snatching is a practice which is 
not restricted to the dark days of the 19th century and will no doubt continue in illicit 
markets for the foreseeable future. Common themes linking all of these examples include: a 
dereliction of basic medical responsibilities by physicians; lack of compassion; complete 
disregard of the dignity and autonomy of the participants (and/or that of the relatives of the 
deceased); the storage of body parts; and, the absence of consent by the participants.   
2.4 Informed consent and tissue banks 
A fundamental requirement of contemporary medical ethics is that of ‘informed consent’ be 
provided by a participant before any study, or procedure, can be performed as discussed 
above (2.2). However, the phrase is fundamentally misleading (Kaye, 2004), since it implies a 
comprehension of the relevant facts and all possible outcomes of the research. However, how 
can non-medically qualified members of the public truly be considered to be fully ‘informed’? 
Indeed, by definition the researchers themselves can only best-guess the possibilities (‘if we 
knew what we were doing, it wouldn't be called research, would it?’ Albert Einstein). This situation is 
exacerbated in the case of biobanks where samples may be used in future research projects that 
have not yet been envisioned using techniques and technologies which have yet to be 
developed. Indeed, one study of biobank donors found that they did not consider themselves 
well informed about what their samples would be used for (Hoeyer et al., 2005).  
This issue was been addressed by the German Ethics Council which takes the view that: ‘if 
donors have been informed of the indefinite nature of the actual future applications, they will be aware 
that they are agreeing to an uncertainty. This uncertainty is not acceptable if it involves more than 
minimum health risk which is not the case with Biobanks’ (Deutscher Ethikrat, 2010). Thus ‘open’ or 
‘broad’ consent to future usage of donated samples has been proposed as best practice for 
biobanks (Hansson et al., 2006). Similarly, the council of Europe’s biobanking recommendation 
acknowledges the conflict between the traditional informed consent and the needs of 
population genetic databases, and as a result stated that consent need not be specific, but it 
must be as specific as possible with regard to unforeseen uses (Council of Europe, 2006).  
Such proposals are not without their critics who see equivalence between the broadening of 
consent and the dilution of ethics which may result in increased public distrust (Hofmann, 
2009). Though others have noted that actually the reverse may be true (Lipworth et al., 2009). 
Some commentators have gone further, suggesting that for genebanks and for population 
databases, informed consent should be abandoned altogether (Kaye, 2004). Furthermore, in 
countries such as the UK where free healthcare is provided to all by the state, there is debate 
as to whether there is an automatic moral obligation upon patients to automatically donate 
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any excess clinical material taken for diagnostic purposes to medical research: i.e. the 
introduction of an ‘opt-out’ as opposed to the current ‘opt-in’ system. Such ‘opt-out’ 
genebanks are already in operation in Europe (e.g. the Vanderbilt DNA databank) and have 
driven the development of new approaches to the governance as well as innovative public 
education and communications strategies (Pulley et al., 2010). 
2.5 Inclusivity of biobanks 
There are many problems facing researchers in gaining the public’s confidence in donating 
samples to biobanks. In the case of donations to genebanks public refusal to consent 
(revealed by a questionnaire) was explained by a lack of personal relevance of the 
contribution and feelings of discomfort related to the possibility that the DNA would be 
used for purposes other than the original study (Melas et al., 2010). The underlying concerns 
revolved around issues of integrity, privacy, suspiciousness, and insecurity. Interestingly 
though despite concerns about privacy another study of 4,569 US participants revealed that 
60% would be willing to participate (Kafam et al., 2009). However, the same study noted that 
ethnic minorities, women and those without a College degree, were concerned that the 
government could gain access to their personal information. Such concerns may be 
translated into an unwillingness not to engage with biobanks. Indeed, there are well 
acknowledged problems in recruiting sufficient organ donations from ethnic minorities 
resulting in a higher mortality amongst these communities from diseases necessitating 
transplants (Bratton et al., 2011; Salim et al., 2010). In the USA educational schemes have 
been introduced and appear to have partially resolved this problem (Callender et al., 2010).   
In industrialized nations the ethical points of reference for regulating medical research have 
inevitably been drawn from classical western moral philosophies and Judeo-Christian 
religious traditions. Relatively recently, the UK population has transformed from a 
predominantly Caucasian European Christian admix into a diverse multi-cultural/ethnic 
society as a result of immigration. Whilst more recent migrants from Eastern Europe share 
many of the cultural and religious traditions of the former, others from Africa, the Indian 
sub-continent and Asia often do not. Research biobanks (like organ donation schemes) need 
to be representative of their communities, consequently they must: (i) appreciate the cultural 
and religious sensitivities of ethnic minorities; (ii) understand historic negative perceptions 
of Western medical research, and, (iii) use this information to insure that ethnic minorities 
become fully engaged in such research projects. 
An example of such cultural differences include Chinese tradition where self-determination 
is not a recognized phenomenon (Bowman & Hui, 2010), meaning that the family –rather 
than the patient- receive clinical information and make decisions to coordinate treatment. In 
Judaism, bodies are buried undisturbed and quickly after death as a matter of respect. 
Discussion within the Jewish faith about whether it is permissible to harvest organs for 
transplant from brain-dead persons is ongoing (Bresnahan & Mahler, 2000). Similarly, 
amongst Hindus and Sikhs the individual is caste-bound in its decision, and there is the 
concept of purification by death/rebirth axis: organ donation or contribution to a biobank 
might be seen to interfere with. In a systematic review of the opinions of twenty-eight major 
religions only one, Shintoism, was noted to be completely antagonistic to the idea of organ 
or tissue donation after death (United Network for Organ Sharing [UNOS], 2000). This is 
based on the concept that the cadaver is impure and dangerous, and injuring it is a serious 
crime as it damages the ‘itai’ (the relationship between the dead and the bereaved).  
Many ethnic minorities resident in industrialized nations also have perceptions of ‘scientific 
imperialism’ or ‘bio-colonialism’ (Emerson et al., 2011) or scientific racism (e.g. the Tuskegee 
study 2.3 above). Not surprisingly there can be considerable distrust of western medical 
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research. A recent example of this was the reticence of the Indonesian government to share 
samples of the H5N1 influenza virus with the international scientific community (Gelling, 
2007). One suggestion to restore public faith is the proposal to establish a tissue trust to serve 
the interests of the common good (Emerson et al., 2011) and would act by involving tissue 
donors and community members in research governance. These issues are of considerable 
importance to the current ‘opt-in’ model for biobanking in the UK. Indeed, for biobanks to be 
effective they must collect tissues from all of the community. Failure to do this may mean that 
downstream medical research using a biobanks samples may effectively result in further 
examples of scientific racism in that some research may be race-specific. These concerns are 
also a persuasive argument for locating biobanks in ethnically-diverse regions of a country. 
Extending this concept of inclusivity further is the idea of harmonizing legal and ethical 
permissions internationally. This is important as a major ambition of biobanks world-wide 
is to establish networks for the international exchange of important clinical samples 
(Pearson, 2004). Whilst differences in national laws may complicate this process it has been 
suggested that if all countries simply abide by the Helsinki Declaration (WMA, 2009) any 
additional regulation would be counterproductive (Hansson, 2011). In contrast, others have 
argued in favour of a greater harmonization of ethics legislation between nations (Chalmers, 
2011). Harmonization of biobank regulation is an important future goal since a survey of 126 
European biobanks noted that most had currently only a very limited networking activity, 
and just a half having policies for cross-border sharing of samples (Zika et al., 2011).  
3. UK regulations and statutory bodies 
In the UK there are three major governmental bodies which regulate medical research. 
Regulation of research ethics is by one of two types of review bodies: universities (e.g. the 
King’s College London’s College Research Ethics Committee) and the government’s 
National Research Ethics Service (NRES, 2007). Whilst there is some overlap between these 
two bodies (e.g. human studies not involving NHS patients can be considered by both, 
investigations using NHS patient samples can only be considered by the latter), most 
medical researchers use the NRES’s local research ethics committees (LREC) scheme. LRECs 
have evolved over recent years so that now specialized committees exist which are trained 
in issues arising from biobanking.  
Storage of human tissues is regulated by a different body, the Human Tissue Authority 
(HTA) and premises keeping human tissues for research are required to hold a specific type 
of HTA licence and are subject to periodic inspections. The definition of tissues by the HTA 
differs considerably from the biological meaning (a collection of the same kind of cells with 
a common structure and function: e.g. muscle, skin and bone). For the HTA, a tissue is 
considered to be a mixture of different cells acting with common purpose (e.g. such as cells 
of the immune system). Thus, blood is considered a tissue under the HTA act, though so too 
are faeces and urine since they also contain a mix of immunological cells. Conversely, a cell-
line derived within a week of isolation from the body is not considered a tissue on the basis 
of its homogeneity. Similarly, hair – not containing cellular architecture - is not regarded by 
the HTA as a tissue. Confusingly, if tissue architecture architecture is immediately disrupted 
the resultant biochemical mix is not considered a tissue by the authority (e.g. DNA extracted 
from a human tissue).   
Anyone who collects, stores, uses, discloses or destroys identifiable personal information 
about living individuals, must also comply with the UK’s 1998 Data Protection Act (DPA) and 
the Common Law duty of confidence. For the deceased, researchers must comply with the 
latter only. Anonymised personal information (as most frequently collected by biobanks) 
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whether concerning the living or the deceased, falls outside the scope of these legal 
requirements. The DPA applies to `personal data´, which are data that relate to a living 
individual who can be identified either from those data alone or from those data taken in 
conjunction with other information that is available to the person who controls the data. When 
gathering identifiable personal information researchers should aim at all times to ensure that 
its processing is defensible as both `fair and lawful´. This requires as much transparency as 
possible about the uses to which data will be put and any risks that might be involved. The net 
effect of the DPA act is that centres which recruit and annoymise human data and clinical 
materials prior to submitting them to a biobank are subject to the provisions of the DPA, thus 
such personal information must be kept secure at all times. Dependent on the nature of the 
human samples being archived the Health and Safety Executive (HSE) will often need to be 
consulted by biobanks, particularly if this includes the use of clinical materials from patients 
infected with dangerous human pathogens (e.g. the IDB below).  
4. The KCL infectious diseases biobank as a model system 
4.1 Vision 
Biological resource collections such as the Multicenter AIDS Cohort Study (Kingsley et al., 
1987) and the Sidney blood bank cohort (Oelrichs et al., 1998) have helped drive important 
advances in the understanding of the pathogenesis of human immunodeficiency virus 
(HIV). In 2005 there were many biobanks in the UK dedicated to the collection of brains or 
cancer biopsies, but no equivalent facility for the collection of materials for HIV, or indeed 
any other infectious diseases, research. Even within Europe only three other biobanks held 
stocks of publicly-accessible material for HIV research, the Spanish HIV biobank (Garcia-
Merino et al., 2009,2010), the Sapienza University HIV biobank in Italy, and the Picardie 
biobank which holds only sera from infected subjects (Chaigneau et al., 2007). A consultation 
exercise with researchers at KCL indicated that an infectious diseases tissue bank facility 
would be welcomed by many. This led to the establishment of a group of clinicians and 
scientists to develop what has now become the KCL IDB. The central issue of the IDB was to 
collect materials which are of significant value to researchers. For example, around this time 
many pathology departments were (and still are) rebranding themselves as biobanks to 
attract research funding. The problem with this approach is that such pathological 
collections are plentiful and the types of samples preserved do not always coincide with the 
requirements of researchers (e.g. materials suitable for molecular biology studies). 
It was therefore established early on that the IDB would not be a genebank, but rather an 
archive of a broad range of clinical materials which would enable a spectrum of proteomic 
and genomic studies to be performed (e.g. containing live lymphocytes, RNA, DNA, plasma, 
sera, cerebro-spinal fluids etc.). These would be prepared and stored to a high-standard and 
fully documented in terms of sample tracking and processing details.  The initial patient 
cohorts selected for study were those infected with pathogens that were of significance to 
the local community and also to local researchers. These were patients infected with HIV, 
hepatitis B virus or, with bacteraemia (especially methicillin-resistant Staphyloccocus aureus). 
In the case of the major sample collection from HIV-infected subjects it was further decided 
to selectively recruit those with particularly interesting clinical histories. For example, those 
initially recruited were HIV-1 clade B infected individuals who either progressed to disease 
unusually quickly (rapid progressors) or, very slowly (long-term non-progressors) as these 
extremes are most likely to yield important answers to the determinants of pathogenesis. 
Importantly, none of these patients were to be receiving medication so that the natural 
history of the infection and disease processes could be studied.  
www.intechopen.com
       
Biomedical Science, Engineering and Technology 
 
770 
4.2 Location and setting 
The IDB is uniquely located for purpose as the local population in Lambeth and Southwark 
is large (~4 million) and extremely diverse. Indeed, after English the second most common 
spoken language is Yaruba (African) and then Portuguese (Lambeth census, 2001). This 
community also suffers from some of the highest rates for HIV infections, the viral 
hepatitides and sexually-transmitted infections in Europe. The prevalence of UK HIV 
infections is highest within this area and over 10% of all UK HIV cases are treated by local 
clinics. This is exemplified by the facts that amongst pregnant women attending St Thomas’ 
Hospital to deliver their babies around 1% are infected with HIV and 2% with hepatitis B 
(Health Protection Agency, 2008). The IDB is embedded within the KCL Department of 
Infectious Diseases which is affiliated to King’s Health Partners and Guy’s And St Thomas’ 
NHS Foundation Trust. The latter hosts an Academic Health Science Centre (AHSC) and 
also an NHS National Institute of Health Research (NIHR) comprehensive BioMedical 
Research Centre (cBRC). The latter offer considerable advantages since it has established 
two clinical research facilities (CRFs) that effectively comprise of two wards and resources 
in which to conduct clinical trials.  
4.3 Ethical permissions for the IDB 
The prerequisites for the IDB’s ethics included the concept of the dignity and autonomy of 
the volunteers yet also acknowledged the uncertain future research uses of biobank 
samples. Thus, the patient’s information sheets and consent forms were designed to make it 
absolutely clear about the uncertainty of future usage. They also make it transparent that 
their samples would probably be used for genetic research and, the possibility that they 
would be used both for academic or commercial research purposes anywhere in the world. 
It is also made clear to participants that their healthcare would be unaffected by their 
decision to donate a sample, that they could withdraw from the biobank project at any time 
(and also demand that previously donated samples be destroyed) in line with most 
recommendations (Gertz, 2008) and that all samples would be annonymised. An additional 
safeguard was that should a downstream third-party researcher make a finding that was 
pertinent to the health care of the volunteer, this information would be passed back up 
through the management chain via the biobank to the clinicians at the tissue collection centre 
(TCC) who could then break the code and advise patients accordingly (since codes linking 
the patient’s NHS number and the biobank code are only held at TCCs). These core 
principles were consequently remarkably similar to those proposed by the German Research 
Ethics Council some four years later (Deutscher Ethikrat, 2010).  
The timing of the establishment of the IDB was far from ideal since the HTA act was just being 
implemented. Like any such legislation it is the interpretation which sets the precedents, a 
process which can take some time. Currently the IDB has ethical permission from the 
Southampton and South West Hampshire Research Ethics Committee (B) which extends until 
2014 (reference # 09/H0504/39) to collect research samples (blood, urine and faeces) and (any) 
residual diagnostic samples from patients (adults, children and infants) with any infectious or 
inflammatory disease who are attending a routine clinical appointment.  
The IDB cannot recruit from patients who are prisoners or those who are incapable of 
providing informed consent (other than children where the parent/guardian can consent for 
them). There are also restrictions for researchers and IDB samples cannot be used for ‘trivial’ 
or ‘controversial’ research projects such as those involving: fertility, reproduction, stem cells, 
cosmetics or animals. The IDB can establish TCCs at any NHS location in England, Wales or 
Northern Ireland with the co-operation with a local medical Consultant. Local NHS R&D 
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offices have to be informed that a TCC is being established but can play no other role in the 
process. The IDB governance committee is also enabled (through devolved ethics powers) to 
act as an LREC and provide ethical opinions upon studies wishing to access IDB samples. 
The IDB stores samples under the authority of an HTA research license held by the Guy’s 
Hospital campus (reference # 12521). This not only covers the storage of materials by the 
IDB, but also those researchers who remove IDB samples to other sites for the duration of 
their ethical permission. A diagram of the IDBs operations is provided (Figure 1). 
 
 
Fig. 1. Management of the IDB. 
4.4 Governance 
The IDB has a Governance Committee comprising of scientists, doctors, representatives of 
funding bodies and of the patients. This Committee is responsible for managing the IDB, 
strategy decisions, insuring that it conforms to current legislative requirements and also to 
local Medical school regulations. The IDB is regularly audited by the internal KCL Medical 
School representatives and by the HTA (~four times in 2010) and the results of these checks 
are passed back to the Governance Committee. Researchers wishing to access the IDB’s 
samples submit a simple two-page application detailing what they propose to do and, the 
type and numbers of samples required. These details are scrutinized by the IDB’s 
Governance Committee for scientific validity and also for any ethical dimensions. If 
successful, researchers sign a materials transfer agreement (MTA) and the samples are 
released.  
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Staff involved in recruiting volunteers must all have completed ‘in house’ courses on 
‘consent taking’, ‘good clinical practice’ and phlebotomy. Copies of these certificates are 
held by the IDB. Members of the IDB staff are also encouraged to undertake an academic 
module in ethics, philosophy and religion (a three year ‘Associate of KCL’ course). The 
Governance Committee has also established a clear policy on charging researchers to access 
the IDB’s material; they may either agree to pay a fixed rate for the individual samples or 
contribute funds towards the salaries of IDB staff, to offset the processing and storage costs 
incurred by the IDB. Researchers are encouraged to approach the IDB early on during the 
preparation of grants so that projected costs can be included in their applications.  
4.5 Quality control 
The IDB utilizes standardized operating procedures (SOPs) based upon EEC standards (ISO 
guideline 34,# 17025:2005) and works within the UNE-EN-ISO 9001:2000 guidelines to 
facilitate future inter-biobank networking capabilities. Samples are continuously tracked from 
the time of venepuncture, the time of courier collection from the TCCs, through to freezing at 
the IDB, with a target of processing >75% of samples within four hours of the bleed. All 
materials from patients with infections are processed in negative-pressure category III 
laboratory and stored in locked -80 ºC freezers. All of the freezers are: on a protected hospital 
electricity supply; alarmed to the IDB’s staff mobile telephones; and, checked daily for 
temperature fluctuations. None of the released samples from the collections have undergone a 
freeze-thaw cycle. Purified DNA samples are tested for the concentration of DNA and, by 
polymerase chain reaction (PCR) amplification of the housekeeping gene β-globin, for the 
absence of PCR inhibitors prior to release. In-house assessment of viral RNA viability has also 
revealed that viral RNA and sequences can be recovered from all plasmas of HIV patients so 
far tested (for those with viral loads of >350 copies per ml). Similarly, an independent analysis 
of human genomic RNA integrity has demonstrated that all of 104 samples were of high-
quality (mean RNA integrity values of 9.3, on a scale where 1=degraded and 10=completely 
intact RNA) and were successfully used to generate DNA for transcriptome analysis 
(Kozlakidis et al., 2011). Ultimately, the IDB aims to have all of its procedures, SOPs and 
operations validated by the International Standards Organisation.  
In addition to merely maintaining the samples under the IDB’s custiodianship we have also 
sought to enhance their research value. For example, for the core cohort of HIV infected 
patients approximately 33.3% of samples have been genotyped for their HLA class I and II 
alleles and their plasma viruses have had their Gag genes sequenced. The Gag region is 
important as protein products of this reading frame are believed to be important 
determinants in viral escape from the innate and adaptive arms of the immune system 
(Deml et al., 2005). To date, several hundreds of full-length Gag genes have been cloned and 
sequenced (and the latter data deposited in Genebank: accession numbers FN597659-
FN600533). These cloned Gag genes are available to researchers by arrangement. The 
intention is to obtain equivalent data for the complete HIV cohort. The other type of quality 
control that the IDB is actively involved in is monitoring that the samples being collected are 
those which are of (a) most clinical significance and (b) representative of the local 
community. Initial analyses of the first 200 HIV patient volunteers indicated that it was 
collecting a population greatly enriched for those with unusual rates of disease progression 
and that the ethnicity of the volunteers matches well with that of the local community 
(Kozlakidis et al., In Press). 
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4.6 Transparancy 
Given the multiplicity of studies that any individual sample may be used in, the Governance 
committee decided that logistically it would be impossible to provide individual volunteers 
with research feedback on their individual samples, despite reports that this is the 
preference of potential volunteers (Meulkamp et al., 2010).  However, the IDB does attempt 
to provide feedback in the types of studies performed and these data are displayed on the 
IDB’s website (http://www.kcl.ac.uk/schools/medicine/research/diiid/centres /pii/ 
biobank/index.html). The IDB has also publicised its mission and was reviewed in Nature 
Medicine (Towie, 2006), has published in Retrovirology (Williams et al., 2009), Biopreservation 
and Biobanking (Kozlakidis et al., 2011) and has made presentations to national and 
international meetings (e.g. the 2010 Biobanking Conference; the European Virology 
Congress in 2008 & 2010, Nuremberg and Como). The IDB director has served on the 
feasibility study of Biobanking in Northern Ireland (NI) for the NI NHS R&D committee 
(2008), the KCL College Research ethics committee and associated sub-committees (2010-) 
and, is chair of the IDB Governance and ethics committees. The IDB has also consulted with 
patient representatives and has, as a consequence, increased its electronic footprint by 
establishing KCL IDB sites on the social networking sites ‘Facebook’ and ‘Linkedin’.  
4.7 Growth of the IDB 
Since sample collection was initiated in January 2007 there has been a logarithmic growth in 
the number of patient visits to TCCs as well as the numbers of studies approved to access 
IDB samples (Figure 2). Indeed, currently the IDB is processing over three litres of 
peripheral venous blood per week. These examples of growth have also been matched by the 
expansion of the IDB into new categories of diseases. These now include those with hepatitis 
C virus or papillomavirus virus infections and patients with inflammatory diseases 
(including: as diabetes, Crohn’s disease, ulcerative colitis, systemic lupus erythematosus, 
and, pre-multiple sclerosis syndrome). Some of the currently approved studies are listed 
(Table 2), and a steady stream of research publications is starting to ensue (Nath et al., 2006, 
2007; Alvarez et al., 2008; Thorborn et al., 2010). In addition, publications arising from the 
contract research work of the IDB are expected to increase significantly (4.8 below).  
 
 
Fig. 2. Year-on-year growth of the IDB’s HIV sample collection. Gray bars indicate the 
recruitment of new patients in total, whereas black bars indicate the number of donations 
per year. 
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T-Regulatory cells in HIV infection 
Ps20 studies  in HIV infections 
The roles of vpu and tetherinin HIV/AIDS pathogenesis 
The control of inflammation in immunity and autoimmunity 
Naive B cell responses in older people 
Gene expression signatures of HIV-1 infection in vivo and in vitro 
ccess and study residual clinical samples made available during routine joint surgery. 
Genetic variations in IL28B on the natural history of hepatitis B and C and their treatment 
response. 
Non-infectious co-morbidities in HIV infection 
Renal function and bone homeostasis in patients starting HAART 
Defining the function of CD161+ CD8+ T cell subsets in HIV infection and their response 
to therapy 
Investigating the effect of Maraviroc on Microbial Translocation in HIV infected 
individuals who are receiving antiretroviral therapy 
The metabolic impact of Darunavir/ritonavir maintenance monotherapy after successful 
viral suppression with standard Atripla in HIV-1-infected patients 
Table 2. Some of the types of studies currently accessing the IDB. 
4.8 The IDB as a contract service 
The IDB’s skill and expertise is also being currently utilized to provide research support for 
clinical studies performed locally, these are often intervention studies and hence require 
independent ethical permissions from LRECs other than that of the IDB. The largest of these is 
currently the KCL Human Immune Response Dynamics (HIRD) study. This ground-breaking 
longitudinal study is investigating the response in humans to vaccination with the H1N1 
(‘swine flu’) influenza vaccine using a protocol was approved by the Brent LREC 
(09/H0717/88). Briefly, the study involves the IDB collecting and archiving of peripheral 
venous blood samples from overnight fasted volunteers at the CRFs. Two pre-vaccination 
samples are harvested and, after vaccination (with PandremixTM H1N1 vaccine: 
GlaxoSmithKline Biologicals Ltd), a further four samples are collected until six weeks post 
vaccination. To date over 170 volunteers have completed the course of bleeds and vaccination.      
5. Conclusions 
This Chapter has summarized the development of some key ethical concepts which 
specifically impinge upon the newly emerging discipline of human tissue biobanking in 
terms of classical notions as well as historical turning points which have resulted in current 
UK legislation. In particular, this paper highlights the fundamental dilemma between the 
rights of the individual and their duty to the society and describes in practical terms how 
the KCL Infectious Diseases Biobank is regulated and managed. Whilst, the essential ethical 
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keystone to any biobank is the principle of informed consent, the effective functioning of a 
biobank necessitate that there should be as few restrictions as possible. A major challenge 
not mentioned above is that of the education of the general public about biobanks as one 
study reported strong evidence that more people are likely to embrace the idea of biobank 
research if they are informed (Gaskell & Gottweis, 2011). Interestingly, they proposed the 
use of social networking sites to promote the concept.  
Now that the IDB has been established for several years most of the governance and ethics 
issues have been established, nevertheless new challenges are arising. Most pressing for the 
immediate future is improving the IDB’s IT and data processing capabilities. This arises 
from the facts that the IDB’s MTA which requires researchers to feedback raw experimental 
data and with some of the initial studies drawing to a close the quantity of information is 
becoming overwhelming. Ultimately though this will eventually permit the IDB to amass a 
detailed database on the patient volunteers and subsequently permit the multivariate 
analyses on these cohorts to identify important pathogenic markers.  
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